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Introduction {#embj201899372-sec-0001}
============

Receptor‐interacting kinases (RIPKs) are components of innate immune receptor signaling complexes where they become ubiquitinated and contribute to NF‐κB‐mediated inflammatory signaling and cell death (Hrdinka & Gyrd‐Hansen, [2017](#embj201899372-bib-0025){ref-type="ref"}; Annibaldi & Meier, [2018](#embj201899372-bib-0003){ref-type="ref"}). The intracellular bacteria‐sensing receptors NOD1 and NOD2 (nucleotide‐oligomerization domain‐containing proteins 1 and 2) stimulate inflammatory signaling by promoting RIPK2 ubiquitination in response to binding of iE‐DAP (D‐glutamyl‐meso‐diaminopimelic acid) and MDP (muramyl dipeptide) constituents of bacterial peptidoglycan, respectively (Girardin *et al*, [2003](#embj201899372-bib-0018){ref-type="ref"}). NOD1/2 signaling contributes to gastro‐intestinal immunity (Philpott *et al*, [2014](#embj201899372-bib-0045){ref-type="ref"}), and genetic variants in NOD2 are the strongest susceptibility factors to Crohn\'s disease---one of the two major inflammatory bowel diseases afflicting millions in Europe and North America alone (Hugot *et al*, [2001](#embj201899372-bib-0026){ref-type="ref"}; Ogura *et al*, [2001](#embj201899372-bib-0040){ref-type="ref"}; Ananthakrishnan, [2015](#embj201899372-bib-0002){ref-type="ref"}). Mutations of NOD2 have also been implicated in other auto‐inflammatory granulomatous pathologies such as Blau\'s syndrome and early‐onset sarcoidosis (Caso *et al*, [2015](#embj201899372-bib-0008){ref-type="ref"}).

Stimulation of NOD2 recruits RIPK2 along with several ubiquitin (Ub) ligases, including IAP (Inhibitor of Apoptosis) proteins and LUBAC (linear ubiquitin chain assembly complex) (Hasegawa *et al*, [2008](#embj201899372-bib-0021){ref-type="ref"}; Bertrand *et al*, [2009](#embj201899372-bib-0005){ref-type="ref"}; Tao *et al*, [2009](#embj201899372-bib-0055){ref-type="ref"}; Damgaard *et al*, [2012](#embj201899372-bib-0011){ref-type="ref"}; Yang *et al*, [2013](#embj201899372-bib-0066){ref-type="ref"}; Watanabe *et al*, [2014](#embj201899372-bib-0063){ref-type="ref"}). These ligases, together with deubiquitinases, coordinate the conjugation of Lys63‐ and Met1‐linked Ub chains (Lys63‐Ub and Met1‐Ub) on RIPK2 to facilitate signal transduction (Hitotsumatsu *et al*, [2008](#embj201899372-bib-0023){ref-type="ref"}; Fiil *et al*, [2013](#embj201899372-bib-0017){ref-type="ref"}; Draber *et al*, [2015](#embj201899372-bib-0013){ref-type="ref"}; Hrdinka *et al*, [2016](#embj201899372-bib-0024){ref-type="ref"}). Lys63‐Ub and Met1‐Ub are central for productive innate immune signaling and transcription of nuclear factor‐κB (NF‐κB) target genes (Hrdinka & Gyrd‐Hansen, [2017](#embj201899372-bib-0025){ref-type="ref"}). Lys63‐Ub is recognized by the TAK1‐TAB 2/3 (TGFβ‐activated kinase 1; TAK1‐binding protein 2/3) kinase complex, and Met1‐Ub is bound by the IKK (IκB kinase) complex through the subunit NEMO (NF‐κB essential modifier; also known as IKKγ). In turn, the kinase complexes are activated, leading to phosphorylation, ubiquitination, and degradation of the NF‐κB inhibitory factor IκBα and activation of MAP kinases (Hrdinka & Gyrd‐Hansen, [2017](#embj201899372-bib-0025){ref-type="ref"}).

XIAP (X‐linked IAP) is indispensable for NOD2 signaling and familial mutations in XIAP that impact on its function cause severe immunodeficiency with variable clinical presentation, including early‐onset chronic colitis in \~20% of afflicted individuals (Bauler *et al*, [2008](#embj201899372-bib-0004){ref-type="ref"}; Krieg *et al*, [2009](#embj201899372-bib-0034){ref-type="ref"}; Damgaard *et al*, [2012](#embj201899372-bib-0011){ref-type="ref"}, [2013](#embj201899372-bib-0012){ref-type="ref"}; Speckmann *et al*, [2013](#embj201899372-bib-0052){ref-type="ref"}; Pedersen *et al*, [2014](#embj201899372-bib-0043){ref-type="ref"}). The ubiquitination of RIPK2 by XIAP facilitates recruitment of LUBAC (Damgaard *et al*, [2012](#embj201899372-bib-0011){ref-type="ref"}), which in turn conjugates Met1‐Ub on RIPK2 (Fiil *et al*, [2013](#embj201899372-bib-0017){ref-type="ref"}). Previous data using small molecule inhibitors suggested that catalytic activity of RIPK2 may contribute to XIAP‐mediated RIPK2 ubiquitination (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}; Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}). Consequently, the activity of RIPK2 has been implicated in a subset of systemic granulomatous inflammatory diseases (Jun *et al*, [2013](#embj201899372-bib-0028){ref-type="ref"}) and, in particular, ablation of *Ripk2* or inhibition of RIPK2 by small‐molecule kinase inhibitors showed benefits in mouse models of multiple sclerosis (Shaw *et al*, [2011](#embj201899372-bib-0050){ref-type="ref"}; Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}) and Crohn\'s disease‐like ileitis (Tigno‐Aranjuez *et al*, [2014](#embj201899372-bib-0057){ref-type="ref"}), positioning RIPK2 as a new target against human inflammatory diseases. However, the molecular basis for the cross‐talk between the kinase activity of RIPK2 and its role as a critical ubiquitinated scaffold downstream of NOD1/2 remains enigmatic.

Here, we reveal that RIPK2 kinase activity is dispensable for NOD2 inflammatory signaling, show that RIPK2 inhibitors function instead by antagonizing XIAP‐binding and XIAP‐mediated ubiquitination of RIPK2, and identify structural features of RIPK2 required for XIAP binding and for the design of efficient small molecule inhibitors of NOD1/2‐RIPK2‐dependent signaling. Our study exemplifies how targeting the ATP‐binding pocket in RIPK2 can be exploited to interfere with the RIPK2‐XIAP interaction for modulation of NOD signaling.

Results {#embj201899372-sec-0002}
=======

RIPK2 kinase activity is dispensable for NOD2 signaling {#embj201899372-sec-0003}
-------------------------------------------------------

Previous reports showed that tyrosine‐kinase inhibitors such as ponatinib, gefitinib, and the RIPK2‐selective kinase inhibitors GSK583 and WEHI‐345 inhibit cellular responses to the NOD2 agonist MDP (or L18‐MDP) by antagonizing RIPK2 function (Tigno‐Aranjuez *et al*, [2010](#embj201899372-bib-0056){ref-type="ref"}; Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}; Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}; Haile *et al*, [2016](#embj201899372-bib-0020){ref-type="ref"}). In concordance, ponatinib and GSK583 inhibited the degradation of IκBα and NF‐κB‐mediated production of the chemokine CXCL8 in a dose‐dependent manner in U2OS/NOD2 cells stimulated with L18‐MDP (Fig [1](#embj201899372-fig-0001){ref-type="fig"}A--C). Of note, the U2OS/NOD2 cells used in this study express doxycycline (DOX)‐inducible HA‐NOD2 and respond to L18‐MDP without addition of DOX due to leakiness of the promoter (Fiil *et al*, [2013](#embj201899372-bib-0017){ref-type="ref"}). Small molecule kinase inhibitors are categorized into multiple classes, depending on their mode of binding (Roskoski, [2016](#embj201899372-bib-0048){ref-type="ref"}). This includes type I inhibitors that interact exclusively within the ATP‐binding pocket, type II inhibitors that bind both to the ATP, and an additional back pocket created when the activation segment of a kinase adopts an inactive conformation, and type III molecules that bind exclusively to this allosteric back pocket. Curiously, we observed that a subset of known RIPK2 inhibitors belonging to different classes displayed potent (nanomolar) cellular activities, including ponatinib (a type II inhibitor) and GSK583 (an ATP‐competitive type I inhibitor), and that these molecules also antagonized NOD2‐mediated ubiquitination of RIPK2 (Figs [1](#embj201899372-fig-0001){ref-type="fig"}C and [EV1](#embj201899372-fig-0001ev){ref-type="fig"}A; Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}). This implied that the kinase activity of RIPK2 is required for its ubiquitination and, thus, for NOD2 responses. To directly investigate this, we first ablated RIPK2 (RIPK2 KO) by CRISPR‐mediated gene editing in U2OS/NOD2 cells (Fig [EV1](#embj201899372-fig-0001ev){ref-type="fig"}B and C). As expected, degradation of IκBα and production of CXCL8 in response to L18‐MDP were completely inhibited in RIPK2 KO cells (Park *et al*, [2007](#embj201899372-bib-0042){ref-type="ref"}; Fig [1](#embj201899372-fig-0001){ref-type="fig"}D and E). Reintroduction of wild‐type (WT) RIPK2 restored RIPK2 ubiquitination and CXCL8 production, and partially restored IκBα degradation, confirming that the signaling defect was due to the absence of RIPK2 (Fig [1](#embj201899372-fig-0001){ref-type="fig"}D and E). Next, RIPK2 KO cells were reconstituted with kinase‐dead human RIPK2 variants in which the ATP‐binding lysine 47 was substituted for arginine (K47R) or the catalytic aspartate 146 in the "HRD" motif (HHD in human RIPK2) was substituted for asparagine (D146N) (Pellegrini *et al*, [2017](#embj201899372-bib-0044){ref-type="ref"}; Figs [1](#embj201899372-fig-0001){ref-type="fig"}F and G, and [EV1](#embj201899372-fig-0001ev){ref-type="fig"}D). Strikingly, introduction of both kinase‐dead RIPK2 mutants restored NOD2 signaling and CXCL8 production to a similar level as with WT RIPK2 in two independent RIPK2 KO clones, showing that the catalytic function is not needed for RIPK2\'s role in NOD2‐dependent inflammatory signaling (Figs [1](#embj201899372-fig-0001){ref-type="fig"}G and H, and [EV1](#embj201899372-fig-0001ev){ref-type="fig"}E).

![RIPK2 kinase activity is dispensable for NOD2 signaling\
A, BIntracellular flow cytometry analysis of CXCL8 in U2OS/NOD2 cells treated with L18‐MDP (200 ng/ml, 4 h) and kinase inhibitors ponatinib (A) or GSK583 (B) as indicated.CPurification of Ub‐conjugates using TUBE pulldowns from U2OS/NOD2 cells after treatment with L18‐MDP (200 ng/ml, 1 h) and ponatinib or GSK583 as indicated. Purified material and lysates were analyzed by immunoblotting, with actin as a loading control.DIntracellular flow cytometry analysis of CXCL8 following L18‐MDP treatment (200 ng/ml, 4 h) of parental U2OS/NOD2 cells and RIPK2 KO cells (clone C5‐2) reconstituted or not with RIPK2.EPurification of Ub‐conjugates from parental U2OS/NOD2 cells and RIPK2 KO cells (clone B7‐1) reconstituted or not with RIPK2, treated with L18‐MDP (200 ng/ml, 1 h). Purified material and lysates were analyzed by immunoblotting. Asterisk indicates a non‐specific signal in the TUBE pulldown samples that co‐migrates with the signal for unmodified RIPK2.FSchematic representation of RIPK2. Numbering below schematic refers to amino acid residues in human RIPK2 and indicate domain boundaries. K47 and D146 are catalytic residues for ATP hydrolysis.GImmunoblot analysis of U2OS/NOD2 RIPK2 KO cells (clone C5‐2) reconstituted with RIPK2 variants or empty vector as indicated and stimulated (or not) with L18‐MDP (200 ng/ml, 1 h).HIntracellular flow cytometry analysis of CXCL8 following L18‐MDP treatment (200 ng/ml, 4 h) of cells described in (G).Data information: Data in (A, B, D, H) represent the mean ± SEM of 2--4 independent experiments, each performed in duplicate. Statistical significance in (A) and (B) is determined in relation to L18‐MDP‐stimulated samples without inhibitor. \*\**P* \< 0.01, n.s., not significant. Two‐way ANOVA was used to determine statistical significance. See also Fig [EV1](#embj201899372-fig-0001ev){ref-type="fig"}.Source data are available online for this figure.](EMBJ-37-e99372-g002){#embj201899372-fig-0001}

![RIPK2 kinase‐dead mutants support NOD2 signaling\
Purification of Ub‐conjugates from THP‐1 cells after treatment with L18‐MDP (200 ng/ml, 1 h) and ponatinib or GSK583 as indicated. Purified material and lysates were analyzed by immunoblotting.Schematic representation of RIPK2 mRNA and protein with indicated positions of RIPK2 gRNA sequences (CRISPR/Cas9 B and C) and epitopes for RIPK2 antibodies used in this study. E1--E11 indicates RIPK2 exons.Identification RIPK2 knockout U2OS/NOD2 cell clones grown from cell cultures transfected with CRISPR/Cas9 vectors targeting RIPK2. Clones B7‐1 and C5‐2 were used in the study.Radioactive *in vitro* RIPK2 kinase assay with RIPK2 variants expressed in U2OS/NOD2 RIPK2 KO cells and purified with anti‐HA. The *in vitro* phosphorylated RIPK2 and universal kinase substrate MBP were separated by SDS--PAGE and exposed to X‐ray film. The inputs and precipitated proteins were analyzed by immunoblotting.Intracellular flow cytometry analysis of CXCL8 following L18‐MDP treatment (200 ng/ml, 4 h) of U2OS/NOD2 RIPK2 KO cells (clone B7‐1) reconstituted with RIPK2 variants or empty vector as indicated.Data information: Data represent the mean ± SEM of at least three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, n.s., not significant. Two‐way ANOVA was used to determine statistical significance.Source data are available online for this figure.](EMBJ-37-e99372-g003){#embj201899372-fig-0001ev}

RIPK2 ubiquitination in response to L18‐MDP was also not affected by the K47R and D146N mutations, which is surprising since kinase inhibitors blocked RIPK2 ubiquitination (Figs [1](#embj201899372-fig-0001){ref-type="fig"}C and [2](#embj201899372-fig-0002){ref-type="fig"}A). Moreover, ponatinib prevented ubiquitination of the kinase‐dead RIPK2 variants after NOD2 stimulation and antagonized their capacity to induce NF‐κB activation (Fig [2](#embj201899372-fig-0002){ref-type="fig"}A and B), suggesting that the inhibition of RIPK2 ubiquitination and NOD2 signaling by ponatinib is independent of its inhibition of RIPK2 kinase activity. Although RIPK2 is a high‐affinity cellular target of ponatinib, the molecule is a promiscuous kinase inhibitor (Fauster *et al*, [2015](#embj201899372-bib-0016){ref-type="ref"}; Najjar *et al*, [2015](#embj201899372-bib-0037){ref-type="ref"}; [Appendix Fig S1A](#embj201899372-sup-0001){ref-type="supplementary-material"}; [Dataset EV1](#embj201899372-sup-0004){ref-type="supplementary-material"}). To determine whether ponatinib\'s inhibitory activity was a result of its binding to RIPK2, we substituted the threonine 95 "gatekeeper" residue with a bulky tryptophan (T95W) to prevent ponatinib\'s binding to the RIPK2 ATP‐binding pocket (Fig [2](#embj201899372-fig-0002){ref-type="fig"}C). We first confirmed that the T95W mutation indeed ablated the binding of ponatinib to RIPK2 in cells at the concentrations used to inhibit signaling using a nano‐bioluminescence resonance energy transfer (nanoBRET) assay (Vasta *et al*, [2018](#embj201899372-bib-0059){ref-type="ref"}) and cellular thermal shift assay (CETSA; Jafari *et al*, [2014](#embj201899372-bib-0027){ref-type="ref"}), which measure cellular target engagement. Use of our recently reported ponatinib‐derived kinase tracer SGC‐590001 (Vasta *et al*, [2018](#embj201899372-bib-0059){ref-type="ref"}) in conjunction with nanoLuc‐RIPK2 showed that the T95W mutation prevented detectable interaction at inhibitor concentrations up to more than 100 nM (Fig [2](#embj201899372-fig-0002){ref-type="fig"}D). In accordance with this and with previous findings (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}), ponatinib (300 nM) induced a substantial thermal shift indicative of binding to WT RIPK2 (and K47R RIPK2), but this was not observed for the RIPK2 T95W and K47R+T95W mutants ([Appendix Fig S1B](#embj201899372-sup-0001){ref-type="supplementary-material"}). Introduction of the T95W mutation, either alone or in combination with kinase‐dead RIPK2 substitutions, largely abolished the inhibitory effect of ponatinib on RIPK2‐induced NF‐κB activation (Fig [2](#embj201899372-fig-0002){ref-type="fig"}B) and on NOD2 signaling as determined by RIPK2 ubiquitination, IκBα degradation, phosphorylation of NF‐κB (p65), and production of CXCL8 (Fig [2](#embj201899372-fig-0002){ref-type="fig"}E and F). Together, these observations show that ponatinib inhibits NOD2 signaling through its binding to RIPK2 but not by inhibiting the kinase activity of RIPK2.

![Ponatinib antagonizes NOD2 signaling through binding to RIPK2 but independently of its kinase activity\
Purification of Ub‐conjugates from U2OS/NOD2 RIPK2 KO cells (clone C5‐2) reconstituted with RIPK2 variants or vector as indicated and treated with L18‐MDP (200 ng/ml, 1 h) and/or ponatinib. Purified material and lysates were analyzed by immunoblotting. Asterisk indicates a non‐specific signal in the TUBE pulldown samples that co‐migrates with the signal for unmodified RIPK2.NF‐κB activity in lysates of HEK293FT cells transfected with dual luciferase NF‐κB reporters and HA‐RIPK2, and treated with DMSO or ponatinib (200 nM, 24 h) as indicated. Relative luciferase activity in ponatinib‐treated samples is shown relative to the activity in the corresponding HA‐RIPK2 transfected sample not treated with inhibitor.Structure of the RIPK2 kinase domain in complex with ponatinib (green) (PDB ID: 4C8B). Sticks are shown for catalytic residues Lys47 (blue) and Asp146 (red), and the gatekeeper residue Thr95 (yellow).NanoBRET assay in HEK293 cells transiently transfected with the NanoLuc‐RIPK2. Cells were treated with serial dilutions of SGC‐590001 probe and incubated with ponatinib (1 μM) or DMSO as a control for 3 h before measurement of BRET ratios. Gray box indicates range of ponatinib concentrations used in signaling experiments in this study.Purification of Ub‐conjugates from U2OS/NOD2 RIPK2 KO cells reconstituted with RIPK2 variants or vector as indicated and treated with L18‐MDP (200 ng/ml, 1 h) and/or ponatinib (100 nM). Purified material and lysates were analyzed by immunoblotting.Intracellular flow cytometry analysis of CXCL8 of U2OS/NOD2 RIPK2 KO cells reconstituted retrovirally with RIPK2 variants or vector as indicated and treated with L18‐MDP (200 ng/ml, 4 h) and ponatinib (50 nM). Values represent CXCL8‐positive cells relative to L18‐MDP treatment for each RIPK2 variant or empty vector.Data information: Data in (B, D, F) represent the mean ± SEM of 3--4 independent experiments, each performed in duplicate. \*\**P* \< 0.01, n.s., not significant. Two‐way ANOVA was used to determine statistical significance. See also [Appendix Fig S1](#embj201899372-sup-0001){ref-type="supplementary-material"}.Source data are available online for this figure.](EMBJ-37-e99372-g004){#embj201899372-fig-0002}

Development of a new series of potent small molecule RIPK2 inhibitors {#embj201899372-sec-0004}
---------------------------------------------------------------------

Ponatinib displays highly promiscuous inhibitory activity (Fauster *et al*, [2015](#embj201899372-bib-0016){ref-type="ref"}; Najjar *et al*, [2015](#embj201899372-bib-0037){ref-type="ref"}), and clinical development of GSK583 was halted (Haile *et al*, [2016](#embj201899372-bib-0020){ref-type="ref"}), raising a need for new classes of RIPK2 inhibitors. We have developed a new chemical series of RIPK2 inhibitors, termed CSLP. A subset of these inhibitors, exemplified by CSLP37 and CSLP43, displayed excellent potency in the NOD2/HEKBlue reporter assay, measuring NF‐κB activation in response to L18‐MDP \[Table [1](#embj201899372-tbl-0001){ref-type="table"}; full details of the synthesis and structure--activity relationship (SAR) will be reported separately (CS, BD, DMP, ALD, LL, MH, LS, MGH, MHU, ANB, AD, GDC, manuscript in preparation)\]. However, correlation analysis of an entire panel of CSLP analogs revealed a startling disparity between inhibition of RIPK2 kinase activity *in vitro* and suppression of the NOD2/RIPK2 pathway in cells. Specifically, while many CSLP inhibitors displayed comparably potent activity against RIPK2 kinase activity *in vitro*, only a small subset of these compounds, i.e., CSLP37/43, provided potent suppression of cellular NOD2/RIPK2‐dependent responses as determined by L18‐MDP‐induced CXCL8 production in U2OS/NOD2 cells and NF‐κB activation in NOD2/HEKBlue cells (Figs [3](#embj201899372-fig-0003){ref-type="fig"}A and B, and [EV2](#embj201899372-fig-0002ev){ref-type="fig"}A; Table [1](#embj201899372-tbl-0001){ref-type="table"}). Of note, CSLP37/43 and other CSLP inhibitors did not have measurable toxicity in the cell lines used in this study (Fig [EV2](#embj201899372-fig-0002ev){ref-type="fig"}B). Additionally, CSLP37 and CSLP43 showed no inhibitory activity against the two closest mammalian homologs of RIPK2, RIPK1, and RIPK3 (Fig [EV2](#embj201899372-fig-0002ev){ref-type="fig"}C).

###### 

*In vitro* and cellular activities of CSLP analogs

  ![](EMBJ-37-e99372-g013.jpg "image")                                                                                              
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  **CSLP43**                             NH~2~   OMe   OMe   ‐NHSO~2~ ^n^Pr   19.9 ± 0.8        1.3 ± 0.4         10.1 ± 3.8        106.9
  **CSLP37**                             NH~2~   F     OMe   ‐NHSO~2~ ^n^Pr   16.3 ± 4.6        26.3 ± 3.7        36.3 ± 20.2       27.1
  **CSLP18**                             NH~2~   H     OMe   ‐NHSO~2~ ^n^Pr   31.6 ± 8.7        476.0 ± 96.7      577.6 ± 34.1      66.6
  **CSLP38**                             NH~2~   F     H     ‐NHSO~2~ ^n^Pr   39.1 ± 1.5        740.3 ± 60.7      166.8 ± 19.0      106.5
  **CSLP48**                             NH~2~   H     OH    ‐NHSO~2~ ^n^Pr   53.5 ± 5.7        \> 5,000          1,231.3 ± 344.5   126.7
  **CSLP53**                             Me      F     OMe   ‐NHSO~2~ ^n^Pr   1,414.5 ± 311.6   2,556.5 ± 252.8   \> 10,000         ND
  **CSLP55**                             NH~2~   F     OMe   OMe              39.1 ± 3.9        595.1 ± 69.6      194.6 ± 47.1      6.8
  **WEHI‐345**                                                                37.3 ± 1.3        3,370.7 ± 382.8   521.2 ± 171.6     7.5

Compounds were tested against recombinant RIPK2 kinase using ADPGlo assay, L18‐MDP‐induced NF‐κB reporter assay (HEKBlue assay), nanoBRET cellular RIPK2 target engagement assay (in HEKBlue cells), and nanoBRET cellular RIPK2 residence time assay (in HEKBLue cells). ND---not determined due to very poor binding of CSLP53 to RIPK2 in nanoBRET assay. For each inhibitor, at least three titrations were performed and data were used to calculate average IC~50~ and SD values. Details of each assays are described in the [Appendix Supplementary Methods](#embj201899372-sup-0001){ref-type="supplementary-material"}. Chemical structure of the CSLP scaffold and WEHI‐345 is shown in above table.

John Wiley & Sons, Ltd

![CSLP series of RIPK2 inhibitors reveal molecular determinants for NOD2 pathway inhibition\
Comparison of inhibitory activity of CSLP compounds on *in vitro* RIPK2 kinase activity (ADPGlo)) and NOD2 signaling in cells (HEKBlue). Compounds characterized further in this study are indicated in red.Intracellular flow cytometry analysis of CXCL8 in U2OS/NOD2 cells treated with L18‐MDP (200 ng/ml, 4 h) and CSLP inhibitors as indicated. Data represent the mean of three independent experiments.Chemical structure of CSLP compounds (18, 37, 43) that differ only in R1 group.Structure of RIPK2 kinase domain in complex with CSLP18 (orange) (PDB ID 6FU5). Sticks are shown for catalytic residues Lys47 and Asp146 (in DFG motif), Glu66 forming a salt bridge to Lys47 in active Glu‐in conformation, and residues involved in binding of CSLP inhibitors as described in the text.Spacefill rendering of RIPK2 kinase domain structure with CSLP18 (top) and models with CSLP37 (bottom left) and CSLP43 (bottom right). Dark gray represents areas occupied by RIPK2; white areas indicate empty spaces in CSLP binding pocket. Dotted white circle indicates cavity occupied by R1 group of CSLP37/43. Dotted black box indicates region shown for models with CSLP37 and CSLP43.Molecular docking model of RIPK2 kinase domain in complex with CSLP43 (green) based on RIPK2/CSLP18 structure from (D). Key residues from CSLP18/RIPK2 structure and residues forming "R1" pocket, Ala45, Lys47, Ile93, Thr97 are shown as sticks.Comparison of the binding poses of CSLP43 (blue) docking model from (E) based on RIPK2/CSLP18 structure (C) with other RIPK2 kinase inhibitors---Compound 7f (PDB ID 5W5O), ponatinib (PDB ID 4C8B), GSK583 (PDB ID 5J7B), and WEHI‐345 (molecular docking model based on RIPK2/CSLP18 structure). While compound 7, ponatinib, GSK583 occupy similar or larger spaces in the deep pocket, WEHI‐345 does not contain groups equivalent to R1 and R3 of CSLP43.Intracellular flow cytometry analysis of CXCL8 of U2OS/NOD2 RIPK2 KO cells reconstituted with WT RIPK2 or T95W mutant, and treated with L18‐MDP (200 ng/ml, 4 h) and CSLP inhibitors as indicated. Values represent CXCL8‐positive cells relative to L18‐MDP treatment for each RIPK2 variant without inhibitor treatment.Data information: Data in (H) represent the mean ± SEM of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, n.s., not significant. Two‐way ANOVA was used to determine statistical significance. See also Fig [EV2](#embj201899372-fig-0002ev){ref-type="fig"}.](EMBJ-37-e99372-g006){#embj201899372-fig-0003}

![Structural basis and selectivity of CSLP mode of RIPK2 inhibition\
Intracellular flow cytometry analysis of CXCL8 of U2OS/NOD2 cells treated with L18‐MDP (200 ng/ml, 4 h) and CSLP inhibitors as indicated.Viability of U2OS/NOD2, THP1, RAW264.7, and HEKBlue cells treated with CSLP inhibitors for 24 h. Cell viability was determined using CellTiter‐Glo assay (Promega). Puromycin (2 or 10 μg/ml) was used as a positive control for cell death.CSLP37 and CSLP43 do not inhibit recombinant RIPK1 and RIPK3 kinases. Kinase activities were determined using ADPGlo assay (Promega).Structure of the active conformation of RIPK2 kinase domain in complex with AMP‐PNP (PDB ID: 5AR3). Figure depicts locations of the adenine and deep pockets. Alignment of two active AMP‐PNP‐bound conformations of RIPK2 (5AR3, green sticks; 5NG0, brown sticks) with CSLP18‐bound RIPK2 (blue sticks) reveals its inactive conformation. Key residues discussed in the text are shown as sticks (Lys/Glu Glu‐in bond---bottom left, catalytic Asp residues (Asp146/Asp164)---bottom right, R‐spine---right). P‐loop of CSLP18 structure is shown in yellow. Structured segment of activation segment (AS) observed in active conformation structures is shown in red.Structure of RIPK2 kinase domain (gray ribbons) in complex with CSLP18 (orange) (PDB ID 6FU5). Sticks are shown for residues in the vicinity of the cavity surrounding the key inhibitor position R1. A 2Fo‐Fc electron density map contoured at 1 sigma is shown for the inhibitor and the residues lining the key region around inhibitor R^1^ position.Molecular docking model of RIPK2 kinase domain in complex with CSLP37 (yellow) based on RIPK2/CSLP18 structure (Fig [3](#embj201899372-fig-0003){ref-type="fig"}D). Key residues from CSLP18/RIPK2 structure and residues forming "R^1^" pocket, Ala45, Lys47, Ile93, Thr95 are shown as sticks.Intracellular flow cytometry analysis of CXCL8 of U2OS/NOD2 RIPK2 KO cells reconstituted retrovirally with RIPK2 wt or T95W mutant treated with L18‐MDP (200 ng/ml, 4 h) and CSLP inhibitors as indicated. Values represent the percent CXCL8‐positive cells relative to L18‐MDP treatment for each RIPK2 variant without inhibitor treatment.Data information: Data in (A--C, G) represent the mean ± SEM of three independent experiments. \*\**P* \< 0.01. Two‐way ANOVA was used to determine statistical significance.](EMBJ-37-e99372-g005){#embj201899372-fig-0002ev}

To identify the reasons for the outstanding cellular activities displayed by CSLP37/43, we focused on a small subset of highly structurally similar CSLP analogs, differing in R^1^, R^2^, and R^3^ substituents, that displayed similar inhibition of RIPK2 *in vitro* but widely variable cellular activity in the NOD2/HEKBlue reporter assay (Table [1](#embj201899372-tbl-0001){ref-type="table"}). We first examined whether these molecules displayed major differences in binding to RIPK2 in cells by using the nanoBRET RIPK2 target engagement assay described above (Fig [2](#embj201899372-fig-0002){ref-type="fig"}D). Indeed, while CSLP37/43 displayed a potent target engagement in‐line with their activities in the HEKBlue reporter assay, other CSLP inhibitors, such as CSLP18, differing from CSLP37/43 only in the R^1^ group, CSLP38 (different R^2^), CSLP55 (different R^3^), CSLP48 (different R^1^ and R^2^), displayed lower target occupancy, correlating with reduced cellular activities (Table [1](#embj201899372-tbl-0001){ref-type="table"}). These data suggested that the identity of the R^1^‐R^3^ groups plays a major role in inhibitor binding to cellular RIPK2, which dictates the ability of CSLP inhibitors to suppress NOD1/2 signaling. We also examined target residence time by determining the time required for a nanoBRET probe to engage RIPK2 after washout of the inhibitor from the cells (t1/2) to further elucidate whether the observed differences in potency may reflect changes in off‐rates of the inhibitors, but found no correlation (Table [1](#embj201899372-tbl-0001){ref-type="table"}, nanoBRET residence time). These data suggested that efficient target engagement is a requisite for potent cellular activity of CSLP molecules, which is dictated by the unique combination of R^1^‐R^3^ substituents.

To further understand the structural contributions of R^1^‐R^3^, we crystallized RIPK2 in complex with CSLP18 (Table [1](#embj201899372-tbl-0001){ref-type="table"}), containing a hydrogen (H) in the R^1^ position compared to fluorine (F) and methoxy (OMe) in CSLP37 and 43, respectively (Fig [3](#embj201899372-fig-0003){ref-type="fig"}C and D; [Table EV1](#embj201899372-sup-0003){ref-type="supplementary-material"}). Overall, the complex with CSLP18 revealed RIPK2 in an inactive conformation previously shown for Type I~1/2~A inhibitors (Wu *et al*, [2015](#embj201899372-bib-0065){ref-type="ref"}; Roskoski, [2016](#embj201899372-bib-0048){ref-type="ref"}). Inhibitors in this class interact exclusively within the ATP‐binding pocket, in which a number of critical residues are misplaced from their active positions. Specifically, when compared to structures of active RIPK2 in complex with the ATP analog AMP‐PNP, the RIPK2‐CSLP18 structure showed mis‐orientation of the catalytic residues Asp146 of the HHD motif and Asp164 of the DFG motif, a slight misalignment of the R‐spine, a shifted P‐loop, and a completely disordered activation segment (AS) which is partially structured in active RIPK2 (Fig [EV2](#embj201899372-fig-0002ev){ref-type="fig"}D). The structure is refined at 3.2 Å resolution, and the electron density map is of sufficient quality in the region of the inhibitor to place the inhibitor and its relevant functional groups with reasonably good precision (Fig [EV2](#embj201899372-fig-0002ev){ref-type="fig"}E). CSLP18 forms two hydrogen bonds to the backbone of the hinge segment residues Glu96 and Met98, and the R^3^ sulfonamide forms a hydrogen bond to Asn151. The R^3^ hydrogen bond helps position the phenyl ring and R^2^ OMe group, which inserts into a sub‐pocket formed by the side chains of Glu66 and Leu70 of the αC‐helix (Fig [3](#embj201899372-fig-0003){ref-type="fig"}D). The R^2^ group of CSLP18 fits the binding pocket snugly. However, the R^1^ position does not optimally fill the hydrophobic pocket (termed deep pocket) formed by the side chains of Ala45, Lys47, Ile93, and gatekeeper Thr95 located on the β3 and β5 strands of the β sheet bundle (Fig [3](#embj201899372-fig-0003){ref-type="fig"}D and E). This is further revealed by the molecular docking of CSLP37 (R^1^ = F) and CSLP43 (R^1^ = OMe), which demonstrates that the larger R^1^ groups of these molecules more optimally fill the deep pocket (Figs [3](#embj201899372-fig-0003){ref-type="fig"}E and F, and [EV2](#embj201899372-fig-0002ev){ref-type="fig"}F). Notably, examining available crystal data, we observed that all previously reported inhibitors that potently antagonize NOD2 signaling, including GSK583, ponatinib, and the recently reported compound 7f (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}; Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}; Najjar *et al*, [2015](#embj201899372-bib-0037){ref-type="ref"}; Haile *et al*, [2016](#embj201899372-bib-0020){ref-type="ref"}; He *et al*, [2017](#embj201899372-bib-0022){ref-type="ref"}), all occupy the deep pocket (Fig [3](#embj201899372-fig-0003){ref-type="fig"}G).

Lastly, consistent with this binding mode and similar to our ponatinib data (Fig [2](#embj201899372-fig-0002){ref-type="fig"}F), inhibition of NOD2 signaling by CSLP37 and CSLP43 was no longer observed in cells expressing a mutant RIPK2 with a bulky tryptophan (W) replacing T95 gatekeeper residue forming part of the pocket occupied by the R^1^ group (Fig [3](#embj201899372-fig-0003){ref-type="fig"}F and H). In contrast, inhibition of signaling by CSLP48 and CSLP55, which displayed poor engagement of cellular RIPK2, was not negatively impacted by the T95W mutation (Fig [EV2](#embj201899372-fig-0002ev){ref-type="fig"}G).

CSLP37/43 selectively inhibit NOD responses in cells and display potent activity *in vivo* {#embj201899372-sec-0005}
------------------------------------------------------------------------------------------

To further establish cellular activities of CSLP37 and CSLP43, we first confirmed that these molecules efficiently blocked MDP‐elicited inflammatory signaling by measuring the release into the media of TNF (tumor necrosis factor), which is stimulated in macrophages in response to NOD2 activation (Ammann *et al*, [2014](#embj201899372-bib-0001){ref-type="ref"}). CSLP37 and CSLP43 blocked the release of TNF in these cells with similar IC~50~ values as determined in the NOD2/HEKBlue assay, while CSLP48 and CSLP55 displayed substantially lower inhibitory activities (Figs [4](#embj201899372-fig-0004){ref-type="fig"}A and B, and [EV3](#embj201899372-fig-0003ev){ref-type="fig"}A). In contrast, neither CSLP37 nor CSLP43 attenuated the TNF release following an unrelated pro‐inflammatory stimulation mediated through Toll‐like receptor 4 (TLR4) activation by LPS, even when used at 1 μM (Fig [EV3](#embj201899372-fig-0003ev){ref-type="fig"}B). Similarly, in experiments with human THP1 monocytes containing an NF‐κB‐SEAP reporter (THP1Blue), CSLP37 and CSLP43 selectively blocked NOD1 and NOD2 responses at low nanomolar concentrations, with no detected effect on NF‐κB responses following stimulation of cells with the non‐NOD agonists: TLR1 and TLR2 agonist Pam3CSK4, LPS, or heat‐killed Listeria monocytogenes (HKLM), which stimulates mainly TLR2 (Fig [4](#embj201899372-fig-0004){ref-type="fig"}C).

![Cellular and *in vivo* characterization of novel RIPK2 inhibitors on inflammatory signaling\
A, BELISA measurement of TNF release from RAW264.7 cells treated with MDP (10 μg/ml, 24 h) and CSLP compounds or RIPK2 inhibitor WEHI‐345 as indicated. Values are expressed relative to the TNF release in cells treated with MDP without inhibitor (A) and are used for calculation of IC~50~ values (B).CInhibition of NF‐κB reporter activity by CSLP37 (top) and CSLP43 (bottom) in THP1Blue cells treated with PRR ligands: MDP (10 μg/ml); TriDAP (10 μg/ml); *E. coli* LPS (10 ng/ml); HKLM (1 × 10^7^ cells/ml; or Pam3CSK4 (10 ng/ml). Inhibition values are used for calculating IC~50~ of MDP and TriDAP responses as shown.DInhibition of MDP‐elicited TNF release by CSLP37 *in vivo*. Mice (*n* = 6 per group) were administered i.p. with 10 mg/kg of WEHI‐345 or CSLP36 30 min prior to the i.p. injections of 100 μg/mouse of MDP. After 4 h, blood was collected by cardiac puncture and circulating levels of TNF were analyzed by ELISA.Data information: Data represent the mean ± SEM of three independent experiments. \*\**P* \< 0.01, n.s., not significant. Two‐tailed unpaired Student\'s *t*‐test was used to determine statistical significance. See also Fig [EV3](#embj201899372-fig-0003ev){ref-type="fig"}.](EMBJ-37-e99372-g008){#embj201899372-fig-0004}

![Activity of select CSLP inhibitors in MDP and LPS‐stimulated RAW264.7 macrophages\
A, BELISA measurement of TNF release from RAW264.7 cells treated with MDP (10 μg/ml, 24 h) (A) or LPS (10 ng/ml) (B) and CSLP compounds as indicated. Values are expressed relative to the TNF release in cells treated with MDP without inhibitor (A) or as ng/ml TNF (B).Data information: Data represent the mean ± SEM of 2--3 independent experiments. Statistical significance in (B) is determined in relation to L18‐MDP‐stimulated samples without inhibitor \**P* \< 0.05, \*\**P* \< 0.01, n.s., not significant. Two‐tailed unpaired Student\'s *t*‐test was used to determine statistical significance.](EMBJ-37-e99372-g007){#embj201899372-fig-0003ev}

Nachbur *et al* ([2015](#embj201899372-bib-0036){ref-type="ref"}) described a promising ATP‐competitive RIPK2 inhibitor, WEHI‐345, which displayed high affinity against RIPK2 kinase *in vitro* but showed \> 10‐fold lower cellular potency (Table [1](#embj201899372-tbl-0001){ref-type="table"}; Fig [4](#embj201899372-fig-0004){ref-type="fig"}A), and only partially inhibited the increase in serum levels of TNF in mice challenged with MDP (Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}). CSLP37 displayed improved cellular potency over WEHI‐345 (Table [1](#embj201899372-tbl-0001){ref-type="table"}), and when compared side‐by‐side with WEHI‐345 in mice challenged with intraperitoneal injection of MDP, pretreatment with CSLP37 potently reduced MDP‐elicited serum TNF levels, whereas WEHI‐345 provided a partial reduction (Fig [4](#embj201899372-fig-0004){ref-type="fig"}D). Overall, these data suggest that CSLP37 and CSLP43 represent a new class of RIPK2 inhibitors, which display comparably high cellular potency to ponatinib and GSK583, strong selectivity toward cellular NOD1/2 responses, and effective inhibitory activity *in vivo*.

Kinase inhibitors antagonize RIPK2‐XIAP interaction to inhibit NOD2 signaling {#embj201899372-sec-0006}
-----------------------------------------------------------------------------

XIAP and cIAPs ubiquitinate RIPK2 following NOD2 stimulation (Damgaard *et al*, [2012](#embj201899372-bib-0011){ref-type="ref"}), and the interaction between the XIAP BIR2 domain and the RIPK2 kinase domain is needed for NOD2 signaling (Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}; Chirieleison *et al*, [2017](#embj201899372-bib-0009){ref-type="ref"}). Small molecule IAP antagonists such as Compound A (CpA) can block NOD2 signaling by interfering with the interaction between XIAP and RIPK2 and thereby prevent the ubiquitination of RIPK2 by XIAP (Fig [5](#embj201899372-fig-0005){ref-type="fig"}A; Krieg *et al*, [2009](#embj201899372-bib-0034){ref-type="ref"}; Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}; Hrdinka *et al*, [2016](#embj201899372-bib-0024){ref-type="ref"}). Considering that ponatinib efficiently blocked RIPK2 ubiquitination and that WEHI‐345 interferes with the IAP‐RIPK2 interaction (Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}), we hypothesized that ponatinib may inhibit NOD2 signaling by interfering with the XIAP‐RIPK2 binding interface. In support of this, pretreatment of cells with ponatinib prevented the co‐immunoprecipitation of endogenous RIPK2 with ectopically expressed HA‐tagged XIAP (Fig [5](#embj201899372-fig-0005){ref-type="fig"}A). Furthermore, addition of ponatinib to cell lysates interfered with the ability of recombinant GST‐tagged XIAP BIR2 domain (GST‐BIR2‐XIAP) bound to Glutathione Sepharose to pull down RIPK2 (Figs [5](#embj201899372-fig-0005){ref-type="fig"}B and [EV4](#embj201899372-fig-0004ev){ref-type="fig"}A). Strikingly, addition of GSK583, CSLP37, or CSLP43 to cell lysates also efficiently antagonized pulldown of RIPK2 by GST‐BIR2‐XIAP. whereas CSLP48 and CSLP55, which displayed lower potency in the cells due to the poor occupancy of the deep pocket of RIPK2, had little effect (Fig [5](#embj201899372-fig-0005){ref-type="fig"}C). The region in the RIPK2 kinase domain (KD) responsible for binding to the XIAP BIR2 domain is not known, and the interaction may therefore be either direct or indirect, involving another cellular component. To test this, GST‐BIR2‐XIAP pulldown experiments were performed with recombinant human RIPK2 kinase domain (KD) instead of cell lysates. Under these conditions, GST‐BIR2‐XIAP binding to RIPK2 was maintained and was still antagonized by GSK583, CSLP37, and CSLP43, indicating that XIAP and RIPK2 interact directly through the XIAP BIR2 domain and the RIPK2 KD (Fig [5](#embj201899372-fig-0005){ref-type="fig"}D). cIAP1 also interacts with RIPK2 via its BIR2 domain, and the interaction can be antagonized by WEHI‐345 (Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}). Akin to this, CSLP37 and CSLP43 both antagonized the interaction between GST‐BIR2‐cIAP1 and RIPK2 in cell lysates (Fig [EV4](#embj201899372-fig-0004ev){ref-type="fig"}B), suggesting that cIAP1 and XIAP interact with RIPK2 through a similar mechanism. In concordance with the observed potency of CSLPs to interfere with the XIAP‐RIPK2 interaction, CSLP37 and CSLP43 inhibited RIPK2 ubiquitination in cells stimulated with L18‐MDP, while CSLP48 and CSLP55 again had little or no effect (Fig [5](#embj201899372-fig-0005){ref-type="fig"}E and [EV4](#embj201899372-fig-0004ev){ref-type="fig"}C and D). Taken together, these data suggest that potent inhibition of NOD2 cellular responses by ponatinib, GSK583, CSLP37, and CSLP43 involves interference with the RIPK2‐IAP binding interface and therefore the critical step of RIPK2 ubiquitination by XIAP.

![RIPK2 inhibitors antagonize NOD2 signaling by interfering with the XIAP‐RIPK2 interaction\
Co‐immunoprecipitation and Western blot analysis of HA‐XIAP (F495A; Ub ligase‐dead) and endogenous RIPK2 from HEK293FT cells treated with IAP antagonist compound A (CpA, 10 μM) or ponatinib (200 nM).Pulldown of RIPK2 from U2OS/NOD2 cell lysates with recombinant GST‐tagged BIR2 domain (residues aa 124--242) from XIAP (GST‐BIR2‐XIAP) in the presence of ponatinib or GSK583 as indicated. Purified material and lysates were analyzed by immunoblotting.Pulldown of RIPK2 from U2OS/NOD2 cell lysates with recombinant GST‐BIR2‐XIAP in the presence of CSLP inhibitors. Inhibitors were used at 100‐fold IC~50~ of RIPK2 kinase activity: ponatinib (10 μM), GSK583 (5 μM), CSLP37 (1.8 μM), 43 (2 μM), 48 (5.7 μM), and 55 (3.9 μM) as indicated. Purified material and lysates were analyzed by immunoblotting.Pulldown of recombinant RIPK2 kinase domain (dephosphorylated) with recombinant GST‐BIR2‐XIAP in the presence of CSLP inhibitors as indicated. Inhibitors were used at the same concentrations as in (C). Purified material and lysates were analyzed by immunoblotting.Purification of Ub‐conjugates from THP‐1 cells after treatment with L18‐MDP (200 ng/ml, 1 h) and CSLP inhibitors as indicated. Purified material and lysates were analyzed by immunoblotting.Data information: Asterisk in (B--D) indicates a cleavage product of GST‐BIR‐XIAP recognized by the GST antibody. See also Fig [EV4](#embj201899372-fig-0004ev){ref-type="fig"}.Source data are available online for this figure.](EMBJ-37-e99372-g010){#embj201899372-fig-0005}

![Inhibition of RIPK2 ubiquitination and cIAP1 binding by CSLP inhibitors\
ACoomassie Blue staining of His Trap and gel filtration purified His6‐GST‐XIAP‐BIR2 WT and D214S recombinant proteins at two different concentrations as indicated.BPulldown of RIPK2 from U2OS/NOD2 cell lysates with recombinant GST‐BIR2‐cIAP1 in the presence of CSLP inhibitors. Inhibitors were used at 100‐fold IC~50~ of RIPK2 kinase activity: CSLP 37 (1.8 μM), 43 (2 μM). Purified material and lysates were analyzed by immunoblotting.C, DPurification of Ub‐conjugates from U2OS/NOD2 cells (C) or THP‐1 cells (D) after treatment with L18‐MDP (200 ng/ml, 1 h) and CSLP compounds as indicated. Purified material and lysates were analyzed by immunoblotting.\
Source data are available online for this figure.](EMBJ-37-e99372-g009){#embj201899372-fig-0004ev}

Mapping of XIAP/RIPK2 binding interface {#embj201899372-sec-0007}
---------------------------------------

Having determined that the BIR2 domain of XIAP interacts directly with the RIPK2 kinase domain, we set out to map the region in RIPK2 responsible for the interaction. For this, we analyzed by SPOT assay the binding of recombinant GST‐BIR2‐XIAP to 15‐mer peptides derived from a walk‐through of the entire RIPK2 coding sequence with a frameshift of 3 amino acids (Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}A; [Dataset EV2](#embj201899372-sup-0005){ref-type="supplementary-material"}). Seven putative interacting peptides were identified in the kinase domain of RIPK2 (Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}A, blue squares; Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}B). These seven peptides were printed in triplicate on a new array and probed with either GST‐tagged WT XIAP BIR2 domain or a BIR2 domain containing a mutation in the IAP‐binding motif groove (D214S) that interferes with RIPK2 binding (Figs [6](#embj201899372-fig-0006){ref-type="fig"}A and [EV4](#embj201899372-fig-0004ev){ref-type="fig"}A, [Dataset EV3](#embj201899372-sup-0006){ref-type="supplementary-material"}; Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}). This showed that the WT BIR2 domain binds predominantly to two RIPK2 peptides, A13 (residues 28‐42), and E6 (residues 163--177; Fig [6](#embj201899372-fig-0006){ref-type="fig"}A and B). Comparison of the binding of WT versus D214S BIR2 domain showed that only the interaction with peptide A13 (position B1, D1, and F1) was reduced when probed with the D214S mutant (Fig [6](#embj201899372-fig-0006){ref-type="fig"}A and B). This region spans β2 and the following β2‐β3 loop of the N‐lobe of the RIPK2 kinase domain (Fig [6](#embj201899372-fig-0006){ref-type="fig"}C and D). Strikingly, single‐residue Ala‐ and Leu‐scanning analysis of the A13 peptide and an overlapping peptide covering the β2‐β3 loop and β3 (residues 37‐51) revealed that mutation of R36, H37, or R41 impaired BIR2 binding (Figs [6](#embj201899372-fig-0006){ref-type="fig"}E and [EV5](#embj201899372-fig-0005ev){ref-type="fig"}C, [Dataset EV4](#embj201899372-sup-0007){ref-type="supplementary-material"}). To investigate the function of the R36/R41 patch, we reconstituted U2OS/NOD2 RIPK2 KO cells with RIPK2 mutants in which R36 and/or R41 were substituted with leucine (Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}D). Mutation of these residues impaired the interaction with GST‐BIR2‐XIAP in pulldown experiments with lysates from the reconstituted cells (Fig [6](#embj201899372-fig-0006){ref-type="fig"}F). Accordingly, the RIPK2 R41L single and R36L/R41L double mutants failed to fully restore NOD2 signaling in the reconstituted cells (Fig [6](#embj201899372-fig-0006){ref-type="fig"}G). Intriguingly, R36 and R41 are surface‐exposed and form a basic patch positioned on top of the deep pocket occupied by the compounds that potently inhibit NOD2 signaling (Figs [6](#embj201899372-fig-0006){ref-type="fig"}H and [EV5](#embj201899372-fig-0005ev){ref-type="fig"}E), implying that the compounds alter the ability of XIAP to interact with the R36/R41 patch (Fig [6](#embj201899372-fig-0006){ref-type="fig"}D).

![Mapping BIR2 XIAP ‐ RIPK2 binding interface\
SPOT peptide assay to probe interaction of recombinant GST‐BIR2‐XIAP with partially overlapping RIPK2 peptides (15‐mers) immobilized to the membrane. The bound BIR2 domain was visualized by HRP‐conjugated anti‐His. Seven potentially interacting peptides (blue boxes) were selected for further validation. 11xHis peptides were spotted as a positive control for anti‐His‐HRP staining (yellow boxes).Table shows the position on membrane shown in (A), amino acid sequence and RIPK2 residue ranges, and structural features of the corresponding region in RIPK2, of the peptides selected for further validation.SPOT peptide array of a peptide corresponding to β3 in RIPK2 (aa 37--51) in which each residue is substituted with alanine (Ala‐scan) or leucine (Leu‐scan) was probed for binding of GST‐XIAP BIR2. Each peptide was spotted in triplicate indicated by \#1--\#3. Yellow box indicates the residues in peptide A13 where binding is reduced by modification.U2OS/NOD2 RIPK2 KO cells reconstituted with RIPK2 variants by retroviral transduction. Cell lysates were analyzed for RIPK2 levels by immunoblotting to confirm equal expression of variants.Alignment of the crystal structure of the wild‐type RIPK2 (5NG0) and D146N (5NG2) and K47R (5NG3) mutants reveals that R36/41 XIAP binding area retains the same conformation.Surface charge representation of XIAP‐BIR2 (left) (PDB ID: 1C9Q) or XIAP‐BIR2 in complex with a SMAC‐like peptide (AIAV; right) (PDB ID: 4J44). AIAV peptide is represented by sticks with space‐filling mesh. The peptide binds in the IBM groove overlapping with the acidic patch bound by RIPK2.\
Source data are available online for this figure.](EMBJ-37-e99372-g011){#embj201899372-fig-0005ev}

![Mapping and functional characterization of XIAP‐binding site on RIPK2\
A, BSPOT peptide array of seven putative interacting peptides of the RIPK2 kinase domain, identified in Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}A, probed with purified GST‐XIAP‐BIR2 (WT or D214S; RIPK2 interaction‐defective mutant), and visualized by anti‐His‐HRP (A). The peptides were spotted and analyzed in triplicates (blue boxes). 11xHis was spotted in triplicate as a positive control for anti‐His‐HRP staining (yellow boxes). Table (right) indicates the position of each peptide on the membrane and the amino acids in human RIPK2 covered by each peptide. Heat map presentation of each spot in the peptide array quantified using ImageJ (B). Values represent the relative intensity of the mean of each peptide triplicate to the mean of the positive control triplicate in the peptide array.CPrimary sequence alignment of the N‐terminal region in RIPK2, including the region represented in A13 peptide. Alignment shows high evolutionary conservation of the region. Residues R36 and R41 studied for XIAP binding are shown in blue.DCartoon representation of the structure of RIPK2 kinase domain (PDB ID: 5AR2). Region represented in A13 peptide is shown in blue. Sticks are shown for R36 and R41 to highlight their surface orientation. RIPK2 inhibitor GSK583 (yellow) is modeled into structure based on PDB ID: 5J7B (Haile *et al*, [2016](#embj201899372-bib-0020){ref-type="ref"}).ESPOT peptide array of the A13 peptide in which each residue is substituted with alanine (Ala‐scan) or leucine (Leu‐scan) was probed for binding of GST‐XIAP‐BIR2. Each peptide is spotted in triplicate indicated by \#1‐\#3. Yellow boxes indicate the residues in A13 where binding is reduced by modification. The bound BIR2 domain was visualized by anti‐His‐HRP.FPulldown of RIPK2 variants from U2OS/NOD2 cell lysates with recombinant GST‐BIR2‐XIAP. Purified material and lysates were analyzed by immunoblotting.GIntracellular flow cytometry analysis of CXCL8 in U2OS/NOD2 RIPK2 KO cells reconstituted with RIPK2 variants following stimulation (or not) with L18‐MDP (200 ng/ml, 4 h). Values represent fraction of CXCL8‐positive cells. Data represent the mean ± SEM of five independent experiments.HStructure of XIAP‐BIR2 (PDB ID: 1C9Q) and RIPK2 kinase domain (KD) (PDB ID: 5AR2). RIPK2 inhibitor GSK583 (yellow) is modeled into the structure based on (PDB ID: 5J7B) (Haile *et al*, [2016](#embj201899372-bib-0020){ref-type="ref"}). Surface charge representation shows an acidic patch around residues E211, D214, and E219 in XIAP and a basic patch generated by R36 and R41 in RIPK2 (black dotted circles). IAP‐binding motif (IBM) groove is indicated by green dotted line in cartoon representation. The inhibitor‐binding pocket is indicated by red dotted line.Data information: \*\**P* \< 0.01, n.s., not significant. Two‐way ANOVA was used to determine statistical significance. See also Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}.Source data are available online for this figure.](EMBJ-37-e99372-g012){#embj201899372-fig-0006}

Discussion {#embj201899372-sec-0008}
==========

Targeting NOD1 and NOD2 signaling with RIPK2 inhibitors is an attractive strategy for the treatment of chronic inflammatory conditions associated with deregulated NOD signaling. These conditions include hereditary auto‐inflammatory syndromes associated with activating mutations in NOD2, such as early‐onset sarcoidosis and Blau syndrome, and early‐onset inflammatory bowel disease, in particular Crohn\'s disease where NOD2 signaling may play an important role (Kanazawa *et al*, [2005](#embj201899372-bib-0030){ref-type="ref"}; Stronati *et al*, [2008](#embj201899372-bib-0054){ref-type="ref"}; Negroni *et al*, [2009](#embj201899372-bib-0038){ref-type="ref"}; Yao *et al*, [2011](#embj201899372-bib-0067){ref-type="ref"}; Caruso *et al*, [2014](#embj201899372-bib-0007){ref-type="ref"}; Uhlig & Schwerd, [2016](#embj201899372-bib-0058){ref-type="ref"}). XIAP‐mediated ubiquitination of RIPK2 emerged as a requisite step in pro‐inflammatory signaling downstream of NOD1 and NOD2 (Bauler *et al*, [2008](#embj201899372-bib-0004){ref-type="ref"}; Damgaard *et al*, [2012](#embj201899372-bib-0011){ref-type="ref"}), and XIAP‐selective IAP antagonists have been recently reported to efficiently impair NOD signaling (Goncharov *et al*, [2018](#embj201899372-bib-0019){ref-type="ref"}). However, continuous inhibition of XIAP as a therapeutic strategy raises concerns due to the role of this protein in innate immune and cell death regulation and because the loss‐of‐function mutations of XIAP associate with hereditary very early‐onset (VEO) IBD and X‐linked lymphoproliferative disease type 2 (XLP‐2) (Rigaud *et al*, [2006](#embj201899372-bib-0047){ref-type="ref"}; Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}; Speckmann *et al*, [2013](#embj201899372-bib-0052){ref-type="ref"}; Latour & Aguilar, [2015](#embj201899372-bib-0035){ref-type="ref"}).

Initial notions that RIPK2 kinase activity facilitates NOD1 and NOD2 signaling were in part based on the finding that kinase activity may be required for RIPK2 stability in cells, and in part, on the fact that kinase inhibitors could inhibit productive NOD1 and NOD2 signaling (Windheim *et al*, [2007](#embj201899372-bib-0064){ref-type="ref"}; Nembrini *et al*, [2009](#embj201899372-bib-0039){ref-type="ref"}; Tigno‐Aranjuez *et al*, [2010](#embj201899372-bib-0056){ref-type="ref"}). However, while several promiscuous clinical Type II inhibitors, such as ponatinib, regorafenib, and sorafenib (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}) displayed very potent (low nanomolar) cellular activity against NOD1‐ and NOD2‐mediated responses, a number of Type I ATP‐competitive inhibitors, such as gefitinib and WEHI‐345, showed reduced potency in cellular assays despite being comparably potent to Type II molecules in inhibiting RIPK2 activity *in vitro* (Tigno‐Aranjuez *et al*, [2010](#embj201899372-bib-0056){ref-type="ref"}; Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}; Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}). In light of these discrepancies, in the present work we sought to define the features of inhibitors necessary for cellular potency against NOD responses.

We started by evaluating the role of RIPK2 catalytic activity in NOD2 signaling. Strikingly, using reconstitution with two different kinase‐dead mutants of RIPK2 we discovered that RIPK2 kinase activity is dispensable for NOD2 inflammatory signaling. Furthermore, ponatinib was still able to completely prevent these responses even in the cells lacking catalytic activity of RIPK2, clearly indicating that efficient inhibition of NOD2 responses is not related to the ability of the inhibitors to block the catalytic activity of RIPK2. Notably, Goncharov *et al* ([2018](#embj201899372-bib-0019){ref-type="ref"}) recently undertook similar experiments and reached the same conclusion that catalytic activity of RIPK2 is not required for NOD2 responses.

As an alternative, we explored whether selected inhibitors may interfere with RIPK2 ubiquitination by XIAP, which is indispensable for NOD1 and NOD2 signaling (Krieg *et al*, [2009](#embj201899372-bib-0034){ref-type="ref"}; Damgaard *et al*, [2012](#embj201899372-bib-0011){ref-type="ref"}, [2013](#embj201899372-bib-0012){ref-type="ref"}). Indeed, we show that all potent NOD pathway inhibitors, including ponatinib, GSK583, and the newly developed CSLP37 and CSLP43 efficiently abrogate both XIAP binding to RIPK2 and RIPK2 ubiquitination. Furthermore, using a panel of closely related CSLP analogs, we show that inhibition of RIPK2 ubiquitination does not generally reflect the affinity of these molecules toward the RIPK2 kinase domain *in vitro*.

This leaves open a critical question of what defines the ability of some, but not all RIPK2 inhibitors to block cellular signaling by interfering with binding of the XIAP BIR2 domain to RIPK2. The crystal structure of one of the CSLP analogs, CSLP18, with RIPK2 provided key insights into this. The RIPK2‐CSLP18 complex structure revealed the inhibitor occupying the ATP pocket of RIPK2 with the R^1^‐R^3^ groups of the inhibitor inserted into the deep pocket behind the adenine‐binding site. Structure--activity relationship analysis of a subset of closely related CSLP analogs revealed that the R^1^‐R^3^ groups dictate high cellular activity of CSLP analogs (Fig [3](#embj201899372-fig-0003){ref-type="fig"}F). Molecular docking analysis showed that two methoxy groups in the R^1^ and R^2^ positions provide an optimal fit in the deep pocket of RIPK2, leading to low nanomolar cellular activity of CSLP43. Consistently, molecules lacking R^1^ or R^2^, or possessing smaller (CSLP37, 18, 38, 48; Table [1](#embj201899372-tbl-0001){ref-type="table"}) or slightly larger (such as R^1^ = Cl or R^2^ = OEt, data not shown, CS, BD, DMP, ALD, LL, MH, LS, MGH, MHU, ANB, AD, GDC, manuscript in preparation) R^1^/R^2^ groups display greatly reduced cellular activity. Additionally, molecules lacking the hydrogen bond acceptor sulfonamide in R^3^ (CSLP55; Table [1](#embj201899372-tbl-0001){ref-type="table"}) also loose cellular activity. The binding of CSLP analogs to RIPK2 in intact HEKBlue cells, measured by nanoBRET assay, closely correlated with the functional activity of the inhibitors in blocking NOD2 signaling. In sum, these data suggested that occupancy of the deep pocket is essential for the ability of CSLP analogs to bind endogenous RIPK2 and to block signaling by interfering with XIAP binding. This "cellular‐specific" role of the deep pocket of RIPK2 contrasts with the more conventional changes that affect affinity of the inhibitors toward RIPK2, such as the absence of the hinge‐interacting amino group in CSLP53, leading to the loss of both *in vitro* and cellular activities.

This mode of activity may also be relevant for other inhibitors since an alignment of published RIPK2 structures indicates that all potent inhibitors of NOD signaling such as ponatinib (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}) and GSK583 (Haile *et al*, [2016](#embj201899372-bib-0020){ref-type="ref"}) extend into the deep pocket occupied by R^1^‐R^3^ substituents of the CSLP series (Fig [3](#embj201899372-fig-0003){ref-type="fig"}G). Another recently described ATP‐competitive RIPK2 inhibitor series with potent activity in cells (e.g., compound 7f) possesses a phenyl ring similar to the CSLP inhibitors (He *et al*, [2017](#embj201899372-bib-0022){ref-type="ref"}). While this molecule lacks a group corresponding to the R^2^ group in the CSLP series, it contains a pyridine and the crystal structure indicates the presence of a water molecule in place of R^2^ in this case (Fig [3](#embj201899372-fig-0003){ref-type="fig"}G). Conversely, the previously reported Type I inhibitor WEHI‐345 likely does not fully occupy the deep pocket as it lacks both R^1^ and R^3^ (Fig [3](#embj201899372-fig-0003){ref-type="fig"}G), which possibly explains its reduced cellular activity (Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}). Overall, these results reveal that while it is possible to inhibit NOD responses using molecules targeting the ATP‐binding pocket, engaging the deep pocket of RIPK2 is critical for the potency of the molecules.

In a complementary set of data, we reveal the molecular interface between RIPK2 and XIAP. Binding data and functional assays suggest that the basic patch formed by R36/R41 located in the N‐terminal loop connecting β2 and β3 mediates XIAP binding via a direct, electrostatic interaction with the acidic patch formed by E211, D214, E219 in the BIR2 IBM groove (Fig [6](#embj201899372-fig-0006){ref-type="fig"}I). This discovery has multiple significant implications. First, it explains why SMAC and some IAP antagonists disrupt the XIAP‐RIPK2 interaction and inhibit NOD2 signaling since these molecules dock into the pocket in the IBM groove and thereby occlude the acidic patch (Krieg *et al*, [2009](#embj201899372-bib-0034){ref-type="ref"}; Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}; Figs [6](#embj201899372-fig-0006){ref-type="fig"}H and [EV5](#embj201899372-fig-0005ev){ref-type="fig"}F). It also explains why charge‐changing mutation of the key IBM groove residues D214 (D214S) and E219 (E219R) interfere with RIPK2 binding, and, possibly, why mutation of the basic H223 residue to a hydrophobic residue (H223V) enhances RIPK2 binding (Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}). Second, identification of the RIPK2/XIAP binding interface offers an opportunity for developing new generations of inhibitors that may possess selectivity toward this interaction as opposed to general inhibition of XIAP functions, some of which may be critical. Third, it raises the question whether the deep pocket of RIPK2 (formed by β3/β5) may possess additional importance because it is located in close proximity and on the opposite side of β3 from the XIAP binding site (Fig [6](#embj201899372-fig-0006){ref-type="fig"}H). One can easily envision that if XIAP binding is associated with movement of β3, molecules occluding the deep pocket in an allosteric fashion could interfere with the binding. Contrary to this, RIPK2\'s ability to mediate NOD2 signaling does not appear to be sensitive to conformational changes elsewhere in the ATP‐binding pocket. Pellegrini *et al* ([2017](#embj201899372-bib-0044){ref-type="ref"}) recently demonstrated significant conformational changes in the ATP‐binding pocket associated with the inactivating mutations D146N and K47R and, yet, we find that both mutants retain the ability to be ubiquitinated by XIAP and mediate signaling in response to NOD2 stimulation. In accordance with this, structural comparison of the RIPK2 R36/R41 XIAP‐binding area indicates there are no significant changes in the conformation between WT RIPK2 and the mutant proteins (Fig [EV5](#embj201899372-fig-0005ev){ref-type="fig"}E).

IAP family members have emerged as important mediators of innate immune receptor responses by ubiquitinating RIPKs within signaling complexes. RIPK2 binds to and is ubiquitinated by both XIAP and cIAP1, but only the interaction with XIAP is required for NOD1 and NOD2 inflammatory signaling, whereas cIAPs are dispensable (Damgaard *et al*, [2013](#embj201899372-bib-0012){ref-type="ref"}; Stafford *et al*, [2018](#embj201899372-bib-0053){ref-type="ref"}). Nonetheless, recent work suggests that TNF‐induced ubiquitination of RIPK1 by cIAPs acts in concert with XIAP‐mediated RIPK2 ubiquitination *in vivo* to provide a full innate immune response to bacterial peptidoglycans (Stafford *et al*, [2018](#embj201899372-bib-0053){ref-type="ref"}). Interestingly, small molecule RIPK2 inhibitors interfere with cIAP1‐binding comparably to XIAP, suggesting that these ubiquitin ligases likely share the binding interface on RIPK2. It is therefore plausible that cIAPs contribute to as yet to be defined RIPK2‐mediated processes. Other innate immune kinases, such as IRAK1 (Interleukin‐1 (IL‐1) receptor‐associated kinase 1) and IRAK4, are ubiquitination targets for other Ub ligases such as TRAF6 and Pellino1 in TLR/IL‐1R signaling (Cohen & Strickson, [2017](#embj201899372-bib-0010){ref-type="ref"}). Remarkably, knowledge about the substrates of RIPK and IRAK kinases is limited and there is a continuing debate about the role of these proteins as true kinases versus their scaffolding function, including as scaffolds for ubiquitination (Kawagoe *et al*, [2007](#embj201899372-bib-0031){ref-type="ref"}; Kim *et al*, [2007](#embj201899372-bib-0032){ref-type="ref"}; Koziczak‐Holbro *et al*, [2008](#embj201899372-bib-0033){ref-type="ref"}; Ordureau *et al*, [2008](#embj201899372-bib-0041){ref-type="ref"}; Song *et al*, [2009](#embj201899372-bib-0051){ref-type="ref"}; Vollmer *et al*, [2017](#embj201899372-bib-0061){ref-type="ref"}; Wang *et al*, [2017](#embj201899372-bib-0062){ref-type="ref"}; Annibaldi & Meier, [2018](#embj201899372-bib-0003){ref-type="ref"}; Dziedzic *et al*, [2018](#embj201899372-bib-0014){ref-type="ref"}). Our findings for RIPK2 exemplify the cross‐talk between the kinase domain serving as a binding interface for a Ub ligase (XIAP) and kinase inhibitors acting as blockers of this interaction. This resolves a paradox of how ATP‐competitive inhibitors of kinase activity may serve to block a scaffolding catalysis‐independent function of the protein. This example may be applicable to other kinases, including other innate immune kinases, whose role in signaling remains enigmatic.

Materials and Methods {#embj201899372-sec-0009}
=====================

Please see [Appendix Supplementary Methods](#embj201899372-sup-0001){ref-type="supplementary-material"} for further details on all methods.

Generation of knockout and reconstituted cell lines {#embj201899372-sec-0010}
---------------------------------------------------

U2OS/NOD2 RIPK2 KO cells were generated using CRISPR/Cas9 KO plasmids (containing gRNA, Cas9, and EGFP reporter; Santa Cruz Biotechnology) as described in Elliott *et al* ([2016](#embj201899372-bib-0015){ref-type="ref"}). Reconstitution with RIPK2 variants was performed by retroviral transduction using pBABE‐Puro plasmids and the retroviral packaging cell line Phoenix‐A. Cells were selected with 1 μg/ml puromycin (InvivoGen) for 1 week.

hNOD2‐HEKBlue and THP1Blue assays {#embj201899372-sec-0011}
---------------------------------

For HEKBlue assay, cells were seeded into clear 96‐well plates at 7.5 × 10^3^ cells/well and allowed to attach for 48 h. On the day of the experiment, media was changed to 100 μl of HEKBlue detection media (InvivoGen). Inhibitors were diluted and added in 0.5 μl DMSO 15 min prior to the addition of 1 ng/ml L18‐MDP (InvivoGen). After 8--9 h, absorbance at 620 nm was measured using Victor3V plate reader (Perkin Elmer, Waltham, MA). Values of media‐only wells were subtracted and %inhibition for each compound concentration relative to the DMSO/L18‐MDP‐treated controls was calculated. Inhibition values ± SD were fitted by non‐linear regression using Prism software (GraphPad Software, La Jolla, CA) to calculate IC~50~ values. For THP1Blue assay, 1 × 10^5^ cells were seeded in 200 μl of RPMI media in 96‐well plates and treated with inhibitors in 0.5 μl DMSO for 15 min prior to the addition of 10 μg/ml MDP, 10 ng/ml Pam3CSK4, 10 ng/ml *E. coli* LPS, or 1 × 10^7^ cells/ml heat‐killed *L. monocytogenes* (InvivoGen) for 24 h. After induction, 20 μl of media was mixed with 180 μl of QUANTI‐Blue reagent (InvivoGen) and incubated at 37°C for 3--4 h, followed by absorbance measurement at 620 nm. IC~50~ values were calculated as described for HEKBlue assay.

Inhibition of MDP‐elicited TNF release *in vivo* {#embj201899372-sec-0012}
------------------------------------------------

Female 6‐ to 8‐week‐old C57Bl6/J mice (Jackson labs) were administered with the compounds i.p. 30 min prior to the i.p. injections of MDP as previously described (Nachbur *et al*, [2015](#embj201899372-bib-0036){ref-type="ref"}). After 4 h, blood was collected by cardiac puncture. 100 μl of serum (diluted twofold) per animal was analyzed using anti‐mouse TNF ELISA (ThermoFisher Scientific).

Recombinant protein expression and purification and ADPGlo kinase assays {#embj201899372-sec-0013}
------------------------------------------------------------------------

The BIR2 domains of XIAP and cIAP1 were cloned into the pGEX‐6P1 vector and were expressed in *E. coli* (BL21) cells as a fusion protein with N‐terminal 6xHis (XIAP BIR2 only) and GST tags. Protein expression was induced with IPTG, and cells were lysed using BugBuster protein extraction reagent (\#70921, Merck Millipore) according to manufacturer\'s instructions. Proteins were purified with the FPLC protein purification system ÄKTA PrimePlus (GE Healthcare Life Sciences) using HisTrap FF column purification followed by gel filtration (HiLoad 26/600 Superdex 75 pg (GE Healthcare Life Sciences)). Collected fractions were stored at −80°C and used for probing of peptide array membranes. Expression and purification of recombinant RIPK1‐3 was performed as previously described (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}; Najjar *et al*, [2015](#embj201899372-bib-0037){ref-type="ref"}). RIPK1‐3 ADPGlo kinase assays using 20 ng/well protein were performed for 2 h at room temperature also as previously described (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}; Najjar *et al*, [2015](#embj201899372-bib-0037){ref-type="ref"}).

Immunoprecipitation, pulldowns, and purification of endogenous ubiquitin conjugates {#embj201899372-sec-0014}
-----------------------------------------------------------------------------------

For co‐immunoprecipitation of HA‐XIAP with RIPK2, transfected and treated cells were lysed in TBS buffer containing 0.5% NP‐40, cOmplete and PhosSTOP inhibitors (Roche) and the lysate was cleared by centrifugation. The lysates were incubated with anti‐HA‐agarose overnight, washed 3× with lysis buffer, and analyzed by immunoblotting. For GST pulldown experiments, U2OS/NOD2 cells were lysed in TBS lysis buffer containing 0.5% NP‐40, cOmplete and PhosSTOP inhibitors (Roche). Cleared lysates were pretreated with kinase inhibitors or DMSO and incubated with GST‐XIAP‐BIR2 bound to Glutathione Sepharose at 4°C overnight. Bound material was washed 3× with lysis buffer or PBS, eluted with 15 mM Glutathione in PBS, and analyzed by immunoblotting. In pulldown experiments with recombinant (dephosphorylated) RIPK2 kinase domain (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}), inhibitors or DMSO control in PBS were added together with RIPK2 kinase domain to GST‐XIAP‐BIR2 bound to Glutathione Sepharose. The bound material was eluted and analyzed as described above. Ubiquitin conjugates were purified from treated cells using GST‐1xUBA^ubq^ ubiquitin affinity reagent (termed TUBE pulldown) and analyzed by immunoblotting as described (Fiil *et al*, [2013](#embj201899372-bib-0017){ref-type="ref"}).

Crystallization and structure determination {#embj201899372-sec-0015}
-------------------------------------------

Crystals were grown using the vapor‐diffusion in sitting drops. The RIPK2:CSLP18 structure was determined as previously described (Canning *et al*, [2015](#embj201899372-bib-0006){ref-type="ref"}).

SPOT peptide assays {#embj201899372-sec-0016}
-------------------

Cellulose‐bound peptide arrays were prepared employing standard Fmoc solid‐phase peptide synthesis using a MultiPep‐RSi‐Spotter (INTAVIS, Köln, Germany) as previously described (Picaud & Filippakopoulos, [2015](#embj201899372-bib-0046){ref-type="ref"}). The assay was performed using recombinant 6xHIS‐GST‐BIR2 domain of XIAP protein, and bound protein was detected using anti‐His antibody HRP‐conjugated. Intensity quantification of SPOTs was performed using ImageJ software (Schneider *et al*, [2012](#embj201899372-bib-0049){ref-type="ref"}).

Dual luciferase reporter assay {#embj201899372-sec-0017}
------------------------------

Cells were co‐transfected the NF‐κB luciferase reporter construct pBIIX‐luc and a thymidine kinase‐renilla luciferase construct. Additional plasmids were transfected where indicated and assay performed as described in Damgaard *et al* ([2012](#embj201899372-bib-0011){ref-type="ref"}).

RIPK2 nanoBRET assay {#embj201899372-sec-0018}
--------------------

HEK293 cells were transiently transfected with the NanoLuc‐RIPK2 WT and T95W mutant RIPK2 constructs, plated into white 384‐well assay plates (Corning, Corning, NY), treated with serial dilutions of SGC‐590001, and incubated with 1 μM ponatinib or DMSO control for 3 h. After addition of Nano‐Glo Substrate (Promega) and Extracellular NanoLuc Inhibitor (Promega), BRET ratios (450 nm and 610 nm) were determined using a PHERAstar FSX plate reader (BMG Labtech). The preparation of SGC‐590001 is described previously (Vasta *et al*, [2018](#embj201899372-bib-0059){ref-type="ref"}). For nanoBRET experiments in HEKBlue cells, cells were transfected with NanoLuc‐RIPK2 WT and stimulated with 1 ng/ml L18‐MDP for 1 h prior to the inhibitor addition. Cell density was adjusted to 2 × 10^5^ cells/ml, and cells were incubated with commercial nanoBRET tracer 6 (Promega) and various inhibitor concentrations for 2 h at 37°C. After that, NanoLuc substrate mix (Promega) was added and BRET ratios were determined using a Victor3V plate reader (PerkinElmer, Waltham, MA). Residence time measurements were performed similarly, except cells were first incubated with the inhibitors, washed carefully to remove un‐bound inhibitor, and then incubated with nanoBRET tracer and NanoLuc substrate. Emission signals were measured 60 times at 2‐min intervals.

Docking experiments and modeling {#embj201899372-sec-0019}
--------------------------------

Ligand docking of CSLP37 and CSLP43 was performed using AutoDock molecular docking software (version 4.2.6) (<http://autodock.scripps.edu/>) with a standard protocol. The co‐crystal structure of CSLP18 bound to RIPK2 was used for the docking experiment where CSLP18 was extracted from the RIPK2 using Discovery Studio 2016 Client software (<http://accelrys.com/>). CSLP37 and CSLP43 ligands were created and subjected to energy minimization using MM2 force field. Grid maps were selected based on CSLP18‐RIPK2 co‐crystal structure, and docking experiments were performed. The final pose was selected based on the lowest binding energy and analyzed using the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC (<https://pymol.org/2/>). Molecular surfaces were generated by mapping electrostatic charge on the models of RIPK2 (PDB: 5AR2) and XIAP (XIAP, PDB:1CQ9) using APBS (Jurrus *et al*, [2018](#embj201899372-bib-0029){ref-type="ref"}) as implemented in PyMOL and are contoured between −10 and +10 kT/e as indicated in the figures.

Data availability {#embj201899372-sec-0020}
-----------------

The accession number for the coordinates and structure factors for the RIPK2 kinase domain bound by CSLP18 is PDB: 6FU5. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository (Vizcaino *et al*, [2013](#embj201899372-bib-0060){ref-type="ref"}) with the dataset identifier PXD009724.

Statistical analysis {#embj201899372-sec-0021}
--------------------

Statistical analysis and calculation of IC~50~ values were performed using Prism 6 (GraphPad Software). Unpaired Student\'s *t*‐test and two‐way ANOVA were used to determine statistical significance as appropriate.
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